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ABSTRACT 
Objective: To develop a simple, accurate and precise reverse-phase high-performance liquid chromatography (RP-HPLC) method and subsequently 
validate for the simultaneous estimation of praziquantel (PZQ) and pyrantel pamoate (PP) in the pharmaceutical dosage form.  
Methods: The chromatographic separation was achieved on Phenomenex Luna C18
Results: The retention time of PZQ and PP was found to be 3.897 min and 1.697 min respectively. The method was validated in terms of specificity, 
accuracy, precision, linearity and robustness as per ICH guidelines. Linearity was obtained in the concentration range of 20–60 μg/ml for both PZQ 
and PP with correlation coefficients of 0.987 and 0.998 respectively. The accuracy of the method was determined using a recovery test and found as 
98.44 % to 100.35 %. All parameters are found to be within the acceptable limit. 
 column (250 mm × 4.6 mm, 5 μm) as st ationary phase 
maintained at an ambient temperature with a mobile phase comprising of water: acetonitrile (20: 80) at a flow rate of 1.0 ml/min and UV detection 
at 220 nm. 
Conclusion: The developed RP-HPLC method was simple, rapid, accurate, precise for the simultaneous estimation of PZQ and PP in bulk and tablet 
dosage form. 
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Helminth infections, which are influenced by parasites, affect more 
than one billion people in the world. Owing to the narrow spectrum 
of anthelmintic drugs it is needed to use combination chemotherapy 
to control mixed infections [1]. 
Chemically PZQ is (11 b RS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-
hexahydro-4H pyrazino [2,1-a] isoquinoline-4-one, shown in fig. 1a, 
is an anthelmintic effective against flatworms. It is very slightly 
soluble in water, freely soluble in chloroform and alcohol. Molecular 
weight of PZQ is 312.4 and the empirical formula is C9H24N2O2
PP chemically designated as 1,4,5,6-tetrahydro-1-methyl-2-[(E)-2-
(2-thienyl)vinyl] pyrimidine hydrogen; 4,4'-Methylenebis(3-
hydroxynaphthalene-2-caroxylate) shown in fig. 1b acts as a 
.  
depolarizing neuromuscular blocking agent causing sudden 
contraction, followed by paralysis of the helminths. It is freely 
soluble in ethanol, methanol, acetone, dimethyl sulfoxide and 
slightly soluble in DMF. The molecular weight is 594.7 and the 
empirical formula is C34H30N2O6
Many analytical methods have been described in the literature for 
the determination of PZQ and PP alone or in combination with other 
drugs using various detection techniques, such as potentiometric 
titration [2], voltammetry [3, 4], spectrophotometry [5-7]. Literature 
review states that few RP-HPLC methods [8-13] and nuclear 
magnetic resonance method [14], high-performance liquid 
chromatography-tandem mass spectrometry methods [15, 16] have 
been reported for the estimation of praziquantel individually and 
with other drug combinations. 
S.  
According to the literature survey, there was no method has been 
reported for the simultaneous estimation of praziquantel and 
pyrantel pamoate by RP-HPLC in combined tablet dosage forms. In 
this study, an HPLC method was optimized and validated for 
simultaneous estimation of praziquantel and pyrantel pamoate in 
tablet formulation in accordance with the ICH guidelines. 
 
Fig. 1a: Praziquantel 
 
 
Fig. 1b: Pyrantel pamoate 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Working reference standards of PZQ and PP was supplied by IPCA 
and Provimi Animal Nutrition Pvt. Ltd, Bangalore. Trial tablets 
procured from Sreenidhi Vet Pharma (250 mg of PZQ and 250 mg of 
PP). HPLC grade acetonitrile and water were purchased from Merck 
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specialties, private Ltd., Mumbai. Methanol and ammonium acetate 
buffer from Finar chemicals Ltd., Ahmedabad respectively.  
Instrumentation and chromatographic conditions 
RP-HPLC (Shimadzu, Japan) equipped with an SPD 20A UV-Visible 
detector, LC-20AT pump and a manual Rheodyne injector with 20 μl 
loops. Column to be used was Phenomenex Luna C18 column (250 
mm × 4.6 mm id, 5 μ particle size ). Data were processed using 
Shimadzu LC solution software. The mobile phase was pumped at a 
flow rate of 1.0 ml/min and UV detection at 220 nm as shown in fig. 
2. Ultra Sonicator (Dakshin, Sakinaka, Mumbai) and Digital analytical 
balance (AUX 220, Shimadzu, Japan) were also used. 
Preparation of standard solutions 
The standard stock solutions containing 1000 µg/ml of PZQ and PP 
were prepared separately by dissolving 10 mg each of reference 
standards in mobile phase [water : acetonitrile (20: 80)] and diluting 
with the same diluent. 0.1 ml aliquots from the standard stock 
solutions of PZQ and PP were transferred to two separate 10 ml 
calibrated volumetric flask and the volume was made up to the mark 
with the same solvent to get a concentration of 10 µg/ml. Calibration 
curve of solutions containing 20-60 µg/ml each of PZQ and PP were 
prepared by diluting the standard stock solution to the appropriate 
volume with the same diluent. A chromatogram of a standard 
preparation of PZQ and PP as shown in fig. 3. 
Preparation of sample solution 
Twenty tablets were weighed and the average weight was found out. 
Tablets were powdered in a mortar and weight equivalent to 10 mg 
each of PZQ and PP was accurately weighed and transferred into 10 
ml calibrated volumetric flask, mixed with acetonitrile, sonicated for 
10 min, and volume was made up to 10 ml with water. An aliquot of 
the supernatant solution was diluted to get a required concentration 
(PZQ 10 μg/ml: PP 10 μg/ml). The identities of both the compounds 
were found out by comparing the retention time of the sample with 
those of standard solution and the results were determined as 
shown in table 1 and fig. 4. 
System suitability 
System suitability is checked to assess whether the developed 
chromatographic conditions are suited for analysis. It is further 
substantiated with accuracy and precision results. A portion of 20 
μg/ml each of standard stock solutions of PZQ and PP was mixed 
into a 10 ml volumetric flask. It was then suitably diluted with 
mobile phase to get a concentration of 20 μg/ml. The resulting 
solution was sonicated for 10 min and 20 μl of this standard solution 
was injected into the HPLC system. System suitability parameters 
are given in table 2. 
Validation of the analytical method 
The developed HPLC method was validated [17-19] as per ICH 
guidelines by various parameters such as specificity, linearity, 
accuracy, precision (Intraday and Inter-day), limit of detection, limit 
of quantification and robustness to ensure that the performance 
characteristic of the method meets the requirement for the intended 
analytical application.  
Specificity 
Specificity is the ability of the method to remain unaffected in the 
presence of components which may be expected to be present. This 
parameter was performed to assess and ensure that the impurities, 
degraded products and diluents do not affect the sample analyzed. 
20 μl of diluent and sample solutions were injected into the system 
and the chromatograms are recorded as shown in fig. 5. 
Linearity and range 
Linearity study was performed from 20-60 μg/ml for PZQ and PP in 
a combination. Suitable concentrations are obtained by diluting the 
stock solution of the drugs. These solutions are chromatographed. 
20 μl of each of the standard solution was injected into the HPLC 
system. From the chromatogram, the peak area for the drugs were 
taken. The linearity curve was plotted individually for PZQ and PP by 
taking a concentration on X-axis and their response factor on the Y-
axis. The correlation coefficient (r2= 0.987 for PZQ and r2
Accuracy 
=0.997 for 
PP) of the regression was found almost equal to 1. Data obtained 
was presented in fig. 6 and 7. 
In accuracy (percentage recovery studies), a known amount of 
standard drug was added to a fixed amount of pre-analyzed sample 
solution. Percent recovery was calculated by comparing the area 
before and after the addition of the standard drug. In the developed 
method, analyte recovery studies were carried out to measure the 
analytes in a complex sample matrix i.e. tablet powder. A spiked 
recovery method has been adopted to check the interference of other 
components of the matrix during the process of separation, detection 
or accurate quantitation of analyte. The recovery at each level is 
determined by comparison to the known amount of pure drugs added. 
In this study standard drug of PZQ and PP spiked at three levels i.e. 80 
%, 100 % and 120 %. Values are presented in table 3. 
Precision 
The precision of an analytical method is the degree of agreement 
among individual test results when the procedure is applied 
repeatedly to multiple samplings of a homogenous sample. Precision 
of an analytical method is usually expressed as standard deviation or 
the relative standard deviation. The values obtained are presented 
in table 4. The repeatability study was assessed by analyzing 3 
different concentration of both drugs (10, 20, 30 μg/ml) on a single 
day and three different days. 
Limit of detection (LOD) 
The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample that can be detected but hasn’t 
necessarily quantitated as an exact value, under the stated 
experimental conditions as given in table 5.  
The signal to noise ratio (S/N) of LOD is 3: 1 or calculated by using 
the following formula  
Limit of detection (LOD)= 3.3 × σ/S  
Limit of quantitation (LOQ)  
The quantitation limit of an individual analytical procedure is the 
lowest amount of analyte in a sample which can be quantitatively 
determined with suitable precision and accuracy.  
The signal to noise ratio (S/N) of LOQ is 10: 1 or calculated by using 
the following equation  
Limit of Quantification LOQ= 10 × σ/S  
Where,  
σ = Standard deviation of Y-intercept.  
S = Slope of the calibration curve. 
Data’s of LOD and LOQ are presented in table 5. 
Robustness 
The robustness of an analytical method was calculated by 
introducing small variations in the HPLC condition which include 
change in flow rate (0.8 and 1.2 ml/min), mobile phase ratio (78, 82 
and 22, 18) and wavelength (218 and 222 nm). Robustness of the 
method was studied using three replicates at the concentration of 30 
μg/ml of PZQ and PP. The data for robustness studies were 
presented in table 6. 
RESULTS 
For developing well suited RP-HPLC method for analysis, 
parameters like detection wavelength, mobile phase composition, 
optimum pH and concentrations of the standard solution were 
comprehensively studied. The working standard solution was 
scanned in the range of 190-400 nm. At 220 nm, both the drugs gave 
satisfactory absorbance with due consideration indifference of their 
concentration and absorbance intensity. Various mobile phases 
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containing methanol, water, acetonitrile, ammonium acetate buffer 
and water with triethanolamine in different ratios were tried with 
different flow rates. The good symmetrical peak was found with the 
mobile phase comprising water and acetonitrile in the ratio 20: 80 
(v/v). Mobile phase was prepared by mixing 200 ml of HPLC grade 
water with 800 ml of acetonitrile of HPLC grade. The mobile phase 




Fig. 2: Overlay spectrum for PZQ and PP in methanol 
 
 
Fig. 3: Chromatogram of a standard preparation of PZQ and PP in water: acetonitrile (20: 80) 
 
 
Fig. 4: Chromatogram for the marketed formulation 
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Fig. 5: Chromatogram for specificity for the solvent water-acetonitrile (20: 80) 
 
Table 1: Analysis of marketed formulation using the proposed RP-HPLC method 
Drug Label claim found Amount (mg/tab) Amount found (%) SD * RSD (%)  
PZQ 250 246 98.4 0.07483 0.08% 
PP 250 236.5 94.6 0.08944 0.11% 
*mean±SD (n=6), SD (Standard deviation), **% RSD (Percentage relative standard deviation) 
 
 
Fig. 6: Calibration curve for PZQ 
 
 
Fig. 7: Calibration curve for PP 
 
Table 2: System suitability parameters 
Parameters PZQ PP    
Linearity range (µg/ml) 20-60 20-60 
Correlation coefficient 0.987 0.997 
Retention time (%RSD)* 3.897 1.697 
Tailing factor (T)* 1.262 1.334 
No. of Theoretical Plates (N) 2784 3039 
Resolution(Rs)* 11.353 - 
Each value is an average of six determinations * (n = 6) 
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Table 3: Data for recovery studies 
Amount of sample 
drug taken (µg) 
Amount of standard drug 
added (µg) 
Total conc. found (µg) Recovery (%)* (%) RSD  
PZQ PP PZQ PP PZQ PP 
10  8 18.14 17.68 99.22  101.8  0.89 0.95 
10 10 20.40 19.79 98.03 101.06 1.05 0.74 
10 12 22.43 22.40 98.08 98.21 0.97 0.68 
 *mean±SD (n=3), SD (Standard deviation), % RSD (Percentage relative standard deviation) 
 
Table 4: Data for Precision studies 
Concentration (µg/ml) Intraday (% RSD)* Intraday (% RSD)* Interday (% RSD)* Interday  (% RSD)*  
PZQ PP PZQ  PZQ  
 20 1.64 0.534 0.906 0.737 
 30 1.74 0.572 1.06 0.408  
40 0.932 0.228 0.457 0.109 
 *mean±SD (n=3), % RSD (Percentage relative standard deviation) 
 
Table 5: LOD and LOQ 
 Test PZQ (μg/ml) PP (μg/ml) 
 LOD 0.161 0.428 
 LOQ 0.4895 1.298  
 
Table 6: Data for robustness studies 
Change in conditions PZQ PP 
Retention time (min) % RSD* Retention time (min)  % RSD*  
Mobile phase     
78: 22 1.665 0.182 4.126 0.254  
80: 20 1.599 0.772 3. 949 0.465 
82: 18 1.609 0.482 3.955 0.351 
Flow rate     
0.8 ml 2.004 0.974 4.938 0.362 
1.0 ml 1.599 0.654 3.949 0.836 
1.2 ml 1.343 0.285 3.301 0.935 
Wavelength     
218 nm 1.592 0.652 3.399 0.681 
220 nm 1.599 0.482 3.949 0.824 
222 nm 1.599 0.681 3.951 0.932 
*The data is expressed as mean±SD (n = 3), % RSD (Percentage relative standard deviation) 
 
DISCUSSION 
In the growing era of international competition for maintaining the 
products standard in high commercial and market value, 
development and validation of analytical method became mandatory 
Analytical method development is the process of demonstrating 
whether an analytical method is acceptable for use in the workplace 
to quantify the concentration of the subsequent sample. The method 
development and validation should be performed as per the 
protocols and acceptance criteria set out in the ICH guideline Q2 
(R1) and used within GMP and GLP environments. 
In the proposed method, chromatographic separation was achieved 
on reversed phase mode for the simultaneous quantification of 
drugs using C18
By using the above method, the assay of the marketed formulation 
was carried out. LOD and LOQ values are 0.161 μg/ml and 0.489 
μg/ml for PZQ, 0.428 μg/ml and 1.298 μg/ml for PP. The robustness 
of the method was evaluated by deliberately varying the 
chromatographic conditions of the method such as, flow rate, mobile 
phase ratio and wavelength. All the parameters were within the 
acceptance criteria. Moreover, in comparison with the method 
described in the literature, the proposed method was found to be 
simple, sensitive and precise. Hence, the developed RP-HPLC assay 
method was found to be appropriate for the analysis of drug in their 
pharmaceutical dosage form 
 column as the stationary phase. The optimized 
isocratic mobile phase condition was water: acetonitrile at (20: 80) 
with a flow rate of 1.0 ml/min for a short run time of 7 min. The 
column temperature was maintained at 30° C. Methanolic solutions 
of PZQ and PP exhibited λ max at 205 nm and 236 nm respectively. 
As the marketed formulation contains the drugs in 1: 1 ratio, the 
decision was made to choose 220 nm as detection wavelength using 
UV-visible detector. These chromatographic conditions gave a 
retention time of 3.897 (indicates high affinity towards mobile 
phase) and 1.697 min for PZQ and PP respectively. The tailing factor 
for both the peaks was found to be<1.5. The ability of the method to 
separate and accurately measure the peak of interests which 
indicate the specificity of the method. The optimized conditions are 
found to be satisfactory with good resolution, high theoretical plate 
value and peak symmetry. The method was validated as per ICH 
guidelines. The specificity studies proved that there is no 
interference from the excipients and other impurities. This method 
shows good Linearity over the range 20-60 μg/ml for both PZQ and 
PP and correlation coefficient was found to be greater than 0.9874 
and 0.9978 respectively for PZQ and PP which was within the limits 
specified (NLT 0.99). The standard addition and recovery studies 
were conducted to demonstrate the accuracy of the method. The 
recovery was found to be in the range of 98 % to 101%, so the 
method can be used for the estimation of PZQ and PP from its dosage 
form without any interference. In all deliberately varied conditions, 
the SD of retention time and the peak area of both drugs were found 
to be within the acceptable limit.  
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A simple, specific, accurate and precise RP-HPLC method has been 
developed and validated for simultaneous estimation of PZQ and PP 
in bulk and combined dosage form. The method provides good 
resolution between the drugs with less retention time. The sample 
recoveries in the formulation were in good agreement with their 
respective label claim. The method was validated as per ICH 
guidelines. So the established method can be successfully applied for 
the routine analysis of the marketed formulations. 
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